Literature DB >> 23360826

Lymphotoxin-α is a novel adiponectin expression suppressor following myocardial ischemia/reperfusion.

Wayne Bond Lau1, Yanqing Zhang, Jianli Zhao, Baojiang Liu, Xiaoliang Wang, Yuexing Yuan, Theodore A Christopher, Bernard Lopez, Erhe Gao, Walter J Koch, Xin L Ma, Yajing Wang.   

Abstract

Recent clinical observations demonstrate adiponectin (APN), an adipocytokine with potent cardioprotective actions, is significantly reduced following myocardial ischemia/reperfusion (MI/R). However, mechanisms responsible for MI/R-induced hypoadiponectinemia remain incompletely understood. Adult male mice were subjected to 30-min MI followed by varying reperfusion periods. Adipocyte APN mRNA and protein expression and plasma APN and TNFα concentrations were determined. APN expression/production began to decline 3 h after reperfusion (reaching nadir 12 h after reperfusion), returning to control levels 7 days after reperfusion. Plasma TNFα levels began to increase 1 h after reperfusion, peaking at 3 h and returning to control levels 24 h after reperfusion. TNFα knockout significantly increased plasma APN levels 12 h after reperfusion but failed to improve APN expression/production 72 h after reperfusion. In contrast, TNF receptor-1 (TNFR1) knockout significantly restored APN expression 12 and 72 h after reperfusion, suggesting that other TNFR1 binding cytokines contribute to MI/R-induced APN suppression. Among many cytokines increased after MI/R, lymphotoxin-α (LTα) was the only cytokine remaining elevated 24-72 h after reperfusion. LTα knockout did not augment APN levels 12 h post-reperfusion, but did so by 72 h. Finally, in vitro treatment of adipocytes with TNFα and LTα at concentrations seen in MI/R plasma additively inhibited APN expression/production in TNFR1-dependent fashion. Our study demonstrates for the first time that LTα is a novel suppressor of APN expression and contributes to the sustained hypoadiponectinemia following MI/R. Combining anti-TNFα with anti-LTα strategies may achieve the best effects restoring APN in MI/R patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360826      PMCID: PMC3602691          DOI: 10.1152/ajpendo.00012.2013

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  32 in total

1.  Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice.

Authors:  Sandra A Schreyer; Cynthia M Vick; Renée C LeBoeuf
Journal:  J Biol Chem       Date:  2002-01-23       Impact factor: 5.157

2.  Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs.

Authors:  M Behrends; R Schulz; H Post; A Alexandrov; S Belosjorow; M C Michel; G Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-09       Impact factor: 4.733

3.  Adiponectin inhibits lymphotoxin-β receptor-mediated NF-κB signaling in human umbilical vein endothelial cells.

Authors:  Yizhou Xu; Chu Zhang; Ningfu Wang; Feng Ling; Peizhang Li; Yan Gao; Wei Hua
Journal:  Biochem Biophys Res Commun       Date:  2010-12-30       Impact factor: 3.575

4.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

Review 5.  Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine.

Authors:  Toshimasa Yamauchi; Kazuo Hara; Naoto Kubota; Yasuo Terauchi; Kazuyuki Tobe; Philippe Froguel; Ryozo Nagai; Takashi Kadowaki
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

6.  Hypoadiponectinemia is closely linked to endothelial dysfunction in man.

Authors:  Michio Shimabukuro; Namio Higa; Tomohiro Asahi; Yoshito Oshiro; Nobuyuki Takasu; Tatsuya Tagawa; Shinichiro Ueda; Iichiro Shimomura; Tohru Funahashi; Yuji Matsuzawa
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

7.  Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation.

Authors:  K C B Tan; A Xu; W S Chow; M C W Lam; V H G Ai; S C F Tam; K S L Lam
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

9.  Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1.

Authors:  R Marfella; M D'Amico; C Di Filippo; E Piegari; F Nappo; K Esposito; L Berrino; F Rossi; D Giugliano
Journal:  Diabetologia       Date:  2002-06-26       Impact factor: 10.122

10.  Association of hypoadiponectinemia with coronary artery disease in men.

Authors:  Masahiro Kumada; Shinji Kihara; Satoru Sumitsuji; Toshiharu Kawamoto; Satoru Matsumoto; Noriyuki Ouchi; Yukio Arita; Yoshihisa Okamoto; Iichiro Shimomura; Hisatoyo Hiraoka; Tadashi Nakamura; Tohru Funahashi; Yuji Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

View more
  3 in total

1.  Glycine is a competitive antagonist of the TNF receptor mediating the expression of inflammatory cytokines in 3T3-L1 adipocytes.

Authors:  Rodrigo Romero-Nava; Francisco J Alarcón-Aguilar; Abraham Giacoman-Martínez; Gerardo Blancas-Flores; Karla A Aguayo-Cerón; Martha A Ballinas-Verdugo; Fausto Sánchez-Muñoz; Fengyang Huang; Santiago Villafaña-Rauda; Julio C Almanza-Pérez
Journal:  Inflamm Res       Date:  2021-04-20       Impact factor: 4.575

Review 2.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

Review 3.  TWEAK: A New Player in Obesity and Diabetes.

Authors:  Joan Vendrell; Matilde R Chacón
Journal:  Front Immunol       Date:  2013-12-30       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.